Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
New research compares MitoQ and SS-31 (Elamipretide) for metabolic liver disease in aged mice. Learn what the findings may mean for future MASLD treatment.
By Peptide Association Research Team
A 2026 Cochrane review examines thymosin alpha-1 therapy for chronic hepatitis B. Learn what the evidence suggests about benefits, harms, and key limitations.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may directly protect neurons via orexin receptor signaling. Learn what this study means for stroke and neuroprotection.
By Peptide Association Research Team
New research explores how SS-31 peptide nanoparticles may restore mitochondrial function and reduce inflammation in ulcerative colitis. Learn what the study found.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may protect neurons by engaging orexin receptors and suppressing necroptosis. Learn what the study found and its implications.
By Peptide Association Research Team
New research suggests the SS-31 peptide may help treat ulcerative colitis by restoring mitochondrial function and reprogramming immune cells. Learn what the study found.
By Peptide Association Research Team
New research shows machine learning may accelerate peptide and protein drug formulation development. Learn what this 2026 study means for peptide therapies.
By Peptide Association Research Team
A 2026 review study explores the complex mechanisms behind acute-on-chronic liver failure, including immune dysfunction and emerging experimental therapies.
By Peptide Association Research Team
A 2026 review explores the complex mechanisms behind acute-on-chronic liver failure, including immune dysfunction and emerging experimental therapies.
By Peptide Association Research Team
A 2026 clinical study suggests HMB supplementation may influence inflammatory patterns and intracellular amino acid synthesis in critically ill ICU patients.
By Peptide Association Research Team
A 2026 case report reveals a child developed severe DKA after starting long-acting growth hormone therapy. Learn what clinicians and patients should know.
By Peptide Association Research Team
New research explores how continuous spin-freeze-drying for PEGylated peptide formulations can be scaled from lab to GMP-compatible production while maintaining quality.
By Peptide Association Research Team
New research explores continuous spin-freeze-drying scale-out for PEGylated peptides, showing consistent quality from lab to GMP production. Learn what this means.
By Peptide Association Research Team
New research shows continuous spin-freeze-drying can scale from lab to GMP manufacturing while preserving peptide quality. Learn what this means for patients.
By Peptide Association Research Team
New research explores scalable freeze-drying for PEGylated peptide formulations. Learn what this manufacturing breakthrough may mean for peptide therapy access.
By Peptide Association Research Team
New research reveals how telehealth rules, NP authority, and compounding infrastructure create major geographic gaps in peptide-based sexual medicine access.
By Peptide Association Research Team
New research explores how DNA methylation and the Wnt signaling pathway may influence Alzheimer's disease progression linked to insulin resistance.
By Peptide Association Research Team
New 2026 research reveals wide geographic disparities in access to peptide-based sexual medicine therapies driven by state telehealth, NP, and compounding laws.
By Peptide Association Research Team
A 2026 clinical study suggests HMB supplementation may support immune response and intracellular amino acid synthesis in critically ill ICU patients.
By Peptide Association Research Team
New research explores GHK-Cu peptide microspheres for bone repair, suggesting dual osteogenic and angiogenic activity in laboratory models. Learn what this means.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may restore cancer-fighting immunity suppressed by chemotherapy. Learn what this 2026 study found and why it matters.
By Peptide Association Research Team
New research explores how L-aspartic acid-derived materials may enable smarter, programmable drug delivery systems. Learn what the science says.
By Peptide Association Research Team
New research explores GHK-Cu peptide microspheres for bone repair. Learn what the study found about osteogenic and angiogenic activity in this evidence-based review.
By Peptide Association Research Team
New research suggests thymosin alpha-1 may help restore anti-tumor immunity after chemotherapy by activating dendritic cells. Learn what the study found.
By Peptide Association Research Team